PL343406A1 - Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists - Google Patents
Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonistsInfo
- Publication number
- PL343406A1 PL343406A1 PL99343406A PL34340699A PL343406A1 PL 343406 A1 PL343406 A1 PL 343406A1 PL 99343406 A PL99343406 A PL 99343406A PL 34340699 A PL34340699 A PL 34340699A PL 343406 A1 PL343406 A1 PL 343406A1
- Authority
- PL
- Poland
- Prior art keywords
- glycyl
- heterocyclic
- beta
- alanine derivatives
- vitronectin antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8139498P | 1998-04-10 | 1998-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL343406A1 true PL343406A1 (en) | 2001-08-13 |
Family
ID=22163868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL99343406A PL343406A1 (en) | 1998-04-10 | 1999-04-09 | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1070060A1 (en) |
| JP (1) | JP2002511462A (en) |
| KR (1) | KR20010042614A (en) |
| CN (1) | CN1304406A (en) |
| AR (1) | AR015759A1 (en) |
| AU (1) | AU765294B2 (en) |
| BR (1) | BR9910119A (en) |
| CA (1) | CA2326665A1 (en) |
| CZ (1) | CZ20003672A3 (en) |
| IL (1) | IL138677A0 (en) |
| MY (1) | MY133473A (en) |
| NO (1) | NO20005084L (en) |
| NZ (1) | NZ507292A (en) |
| PL (1) | PL343406A1 (en) |
| RU (1) | RU2215746C2 (en) |
| TW (1) | TWI247008B (en) |
| WO (1) | WO1999052896A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69930764D1 (en) * | 1998-12-23 | 2006-05-18 | G D Searle Llc St Louis | USE OF CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION TREATMENT OF NEOPLASIA |
| JP2002536411A (en) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | Lactam inhibitors of factor Xa and methods |
| EE200100528A (en) | 1999-04-12 | 2003-02-17 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compound, pharmaceutical composition containing it and their therapeutic use |
| GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| SK15342001A3 (en) * | 1999-04-28 | 2002-06-04 | Basf Aktiengesellschaft | Integrin receptor antagonists |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| ATE375330T1 (en) | 2000-04-17 | 2007-10-15 | Ucb Pharma Sa | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6720315B2 (en) | 2000-06-15 | 2004-04-13 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives |
| US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
| CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| DE10204789A1 (en) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitors of the integrin alpha¶v¶beta6 |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| JP2006514050A (en) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | R isomers of β-amino acid compounds as integrin receptor antagonist derivatives |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| AU2008313733A1 (en) | 2007-10-18 | 2009-04-23 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
| EP2065381A1 (en) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP antagonists |
| JP5385297B2 (en) | 2007-11-22 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New compounds |
| EP2225237A2 (en) * | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organic compounds |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| EP2875021B1 (en) | 2012-07-18 | 2017-08-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| MX2016015467A (en) | 2014-05-30 | 2017-03-23 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators. |
| KR20180107121A (en) | 2015-12-30 | 2018-10-01 | 세인트 루이스 유니버시티 | Meta-azacyclic aminobenzoic acid derivatives as pan integrin antagonists |
| HUE053620T2 (en) * | 2016-11-08 | 2021-07-28 | Bristol Myers Squibb Co | Pyrrole amides as alpha v integrin inhibitors |
| CA3182964A1 (en) | 2020-05-14 | 2021-11-18 | Ube Corporation | 1,4,5,6-tetrahydropyrimidin-2-amine derivative |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| WO2023085396A1 (en) * | 2021-11-12 | 2023-05-19 | Ｕｂｅ株式会社 | Pharmaceutical composition for providing treatment for or preventing alport syndrome |
| CN115626912B (en) * | 2022-09-27 | 2024-03-26 | 中山大学 | Thiourea compound and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| RO118290B1 (en) * | 1995-08-30 | 2003-04-30 | Gdsearle & Co | Phenyl carbonyl urea derivatives and pharmaceutical composition |
| DE19629816A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| CA2263999A1 (en) * | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
-
1999
- 1999-04-09 TW TW088105718A patent/TWI247008B/en active
- 1999-04-09 CN CN99807091A patent/CN1304406A/en active Pending
- 1999-04-09 AU AU34499/99A patent/AU765294B2/en not_active Ceased
- 1999-04-09 CA CA002326665A patent/CA2326665A1/en not_active Abandoned
- 1999-04-09 PL PL99343406A patent/PL343406A1/en unknown
- 1999-04-09 JP JP2000543454A patent/JP2002511462A/en active Pending
- 1999-04-09 NZ NZ507292A patent/NZ507292A/en unknown
- 1999-04-09 WO PCT/US1999/004297 patent/WO1999052896A1/en not_active Application Discontinuation
- 1999-04-09 IL IL13867799A patent/IL138677A0/en unknown
- 1999-04-09 CZ CZ20003672A patent/CZ20003672A3/en unknown
- 1999-04-09 EP EP99916119A patent/EP1070060A1/en not_active Withdrawn
- 1999-04-09 AR ARP990101636A patent/AR015759A1/en unknown
- 1999-04-09 KR KR1020007011291A patent/KR20010042614A/en not_active Application Discontinuation
- 1999-04-09 BR BR9910119-0A patent/BR9910119A/en not_active IP Right Cessation
- 1999-04-09 RU RU2000128033/04A patent/RU2215746C2/en not_active IP Right Cessation
- 1999-04-10 MY MYPI99001398A patent/MY133473A/en unknown
-
2000
- 2000-10-09 NO NO20005084A patent/NO20005084L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999052896A1 (en) | 1999-10-21 |
| TWI247008B (en) | 2006-01-11 |
| CA2326665A1 (en) | 1999-10-21 |
| JP2002511462A (en) | 2002-04-16 |
| NZ507292A (en) | 2003-12-19 |
| CZ20003672A3 (en) | 2001-08-15 |
| MY133473A (en) | 2007-11-30 |
| CN1304406A (en) | 2001-07-18 |
| EP1070060A1 (en) | 2001-01-24 |
| BR9910119A (en) | 2001-10-09 |
| AU3449999A (en) | 1999-11-01 |
| NO20005084L (en) | 2000-11-27 |
| NO20005084D0 (en) | 2000-10-09 |
| RU2215746C2 (en) | 2003-11-10 |
| KR20010042614A (en) | 2001-05-25 |
| AU765294B2 (en) | 2003-09-11 |
| IL138677A0 (en) | 2001-10-31 |
| AR015759A1 (en) | 2001-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL343406A1 (en) | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists | |
| IL145357A0 (en) | Amide derivatives | |
| SI1165516T1 (en) | Heterocyclic urea and related compounds useful as anti-inflammatory agents | |
| HK1048636A1 (en) | N-(indolcarbonyl-)piperazin derivatives | |
| HUP0202450A3 (en) | N-heterocyclic derivatives as nos inhibitors | |
| GB9929973D0 (en) | Heterocyclic compounds | |
| IL148058A0 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
| DK1153014T3 (en) | Beta-alanine derivatives | |
| IL150357A0 (en) | Substituted piperazine derivatives as mtp inhibitors | |
| GB0026578D0 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| AP2002002413A0 (en) | Heterocyclic compounds inhibiting angiogenesi | |
| IL150862A0 (en) | Heterocyclic amide derivatives | |
| PL352409A1 (en) | Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane | |
| IL150010A0 (en) | Heterocyclic derivatives | |
| IL141602A0 (en) | Bridged heterocyclic derivatives | |
| GB0027548D0 (en) | Bicyclic amide derivatives | |
| GB9903337D0 (en) | Heterocyclic derivatives | |
| GB9929038D0 (en) | Heterocyclic derivatives | |
| SI1198453T1 (en) | N-(indolcarbonyl-)piperazin derivatives | |
| GB9912782D0 (en) | Pyrimidine derivatives | |
| GB9809351D0 (en) | Heterocyclic derivatives | |
| GB9812410D0 (en) | Heterocyclic derivatives | |
| GB0009452D0 (en) | PTP1B-Inhibiting heterocyclic derivatives | |
| GB0001972D0 (en) | Heterocyclic derivatives | |
| GB0001993D0 (en) | Heterocyclic derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |